Objective The objective of this study was to use real-world data to evaluate the effectiveness and safety of canakinumab in Italian patients with systemic JIA (sJIA). Methods A retrospective multicentre study of children with sJIA was performed. Clinical features, laboratory parameters and adverse events were collected at baseline, and 6 and 12 months after starting canakinumab. The primary outcome measure of effectiveness was clinically inactive disease (CID) off glucocorticoids (GCs) treatment at 6 months. Results A total of 80 children from 15 Italian centres were analysed. Of the 12 patients who started canakinumab in CID while receiving anakinra, all maintained CID. Of the 68 with active disease at baseline, 57.4% achieved CID off GCs at 6 months and 63.8% at 12 months. In univariate analysis, the variables significantly related to non-response were number of active joints (NAJs) >= 5, history of macrophage activation syndrome (MAS) and disease duration. Multivariate analysis confirmed the association between non-response and NAJs >= 5 [odds ratio (OR) 6.37 (95% CI: 1.69, 24.02), P = 0.006] and between non-response and history of MAS [OR 3.53 (95% CI: 1.06, 11.70), P = 0.039]. No serious adverse events were recorded in this series. There were two cases of MAS during canakinumab, leading to a rate of 2.9 episodes per 100 patient years. Conclusion We have confirmed, using real-world data, the efficacy of canakinumab in sJIA in a multicentric cohort. History of MAS and higher NAJ were associated with lower probability of achieving CID.

Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort

Licciardi, Francesco;Montin, Davide;Conti, Giovanni;
2022-01-01

Abstract

Objective The objective of this study was to use real-world data to evaluate the effectiveness and safety of canakinumab in Italian patients with systemic JIA (sJIA). Methods A retrospective multicentre study of children with sJIA was performed. Clinical features, laboratory parameters and adverse events were collected at baseline, and 6 and 12 months after starting canakinumab. The primary outcome measure of effectiveness was clinically inactive disease (CID) off glucocorticoids (GCs) treatment at 6 months. Results A total of 80 children from 15 Italian centres were analysed. Of the 12 patients who started canakinumab in CID while receiving anakinra, all maintained CID. Of the 68 with active disease at baseline, 57.4% achieved CID off GCs at 6 months and 63.8% at 12 months. In univariate analysis, the variables significantly related to non-response were number of active joints (NAJs) >= 5, history of macrophage activation syndrome (MAS) and disease duration. Multivariate analysis confirmed the association between non-response and NAJs >= 5 [odds ratio (OR) 6.37 (95% CI: 1.69, 24.02), P = 0.006] and between non-response and history of MAS [OR 3.53 (95% CI: 1.06, 11.70), P = 0.039]. No serious adverse events were recorded in this series. There were two cases of MAS during canakinumab, leading to a rate of 2.9 episodes per 100 patient years. Conclusion We have confirmed, using real-world data, the efficacy of canakinumab in sJIA in a multicentric cohort. History of MAS and higher NAJ were associated with lower probability of achieving CID.
2022
61
4
1621
1629
canakinumab; clinically inactive disease; systemic juvenile idiopathic arthritis; Antibodies, Monoclonal, Humanized; Child; Glucocorticoids; Humans; Retrospective Studies; Arthritis, Juvenile; Macrophage Activation Syndrome
De Matteis, Arianna; Bracaglia, Claudia; Pires Marafon, Denise; Piscitelli, Anna Lucia; Alessio, Maria; Naddei, Roberta; Orlando, Francesca; Filocamo, Giovanni; Minoia, Francesca; Ravelli, Angelo; Tibaldi, Jessica; Cimaz, Rolando; Marino, Achille; Simonini, Gabriele; Mastrolia, Maria Vincenza; La Torre, Francesco; Tricarico, Ilaria; Licciardi, Francesco; Montin, Davide; Maggio, Maria Cristina; Alizzi, Clotilde; Martini, Giorgia; Civino, Adele; Gallizzi, Romina; Olivieri, Alma Nunzia; Ardenti Morini, Francesca; Conti, Giovanni; De Benedetti, Fabrizio; Pardeo, Manuela
File in questo prodotto:
File Dimensione Formato  
PArde2022.pdf

Accesso riservato

Dimensione 419.96 kB
Formato Adobe PDF
419.96 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1877980
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 7
social impact